“The stem cell collaboration with JCVI is an exciting opportunity to move our technology into new areas as cell lineage progression studies are becoming important in a wide range of NGS applications,” said Francisco De La Vega, VP of Genome Sciences at Real Time Genomics. "At the same time, a problem in clinical applications of sequencing is the difficulty knowing whether sequencing data and results meet a specific accuracy criteria. RTG and the broader community are working to collectively settle on a set of validated datasets to improve research. Because JCVI has considerable orthogonal information related to the Venter reference genome, including Sanger long-read sequence data, data from multiple next-generation sequencing platforms, and even RNAseq data and full phasing information, there is an opportunity to contribute a standard back to the community to improve the sensitivity and specificity of human disease applications using NGS.”
About Real Time Genomics, Inc.
Real Time Genomics (http://www.realtimegenomics.com) has a passion for genomics. The company offers software tools and applications for the extraction of unique value from genomes. Its competency lies in applying the combination of its patented core technology and deep computational expertise in algorithms to solve problems in next generation genomic analysis. Real Time Genomics is a private San Francisco based company backed by investment from Catamount Ventures, Lightspeed Venture Partners, and GeneValue Ltd.
Read the full story at http://www.prweb.com/releases/2013/5/prweb10687391.htm.
Copyright©2012 Vocus, Inc.
All rights reserved